Related Experiment Videos
Urolithiasis associated with the protease inhibitor indinavir
R G Bruce1, L C Munch, A D Hoven
1Department of Surgery (Urology), University of Kentucky Chandler Medical Center, Lexington 40536, USA.
Urology
|October 24, 1997
Summary
The protease inhibitor indinavir is linked to kidney stone formation in patients with human immunodeficiency virus. Indinavir may form the core of mixed urinary stones, sometimes requiring surgery.
Area of Science:
- Nephrology
- Pharmacology
- Infectious Diseases
Background:
- Protease inhibitors are crucial in managing human immunodeficiency virus (HIV) infection.
- Indinavir is a widely prescribed protease inhibitor for HIV treatment.
Observation:
- Three adult HIV patients on indinavir developed surgical renal stones.
- Stone analysis revealed indinavir components and hypocitraturia.
Findings:
- Indinavir is associated with urolithiasis development.
- The drug may act as a nidus for heterogeneous nucleation, forming mixed urinary stones.
- Hypocitraturia was an isolated metabolic finding in affected patients.
Implications:
- Surgical intervention may be necessary for indinavir-associated urolithiasis.
- Healthcare providers should recognize this association for appropriate management.
- Combined medical and surgical approaches may be required.